Organic and Medicinal Chemistry in Drug Discovery: Pharma's Intelligent Design

Table of Contents

Chapter 1: Executive Summary

• Evolution of Organic and Medicinal Chemistry in the Pharmaceutical Industry
• Current Approaches to Organic and Medicinal Chemistry
• Products and Services
• Organic and Medicinal Chemistry Market
• Scope and Nature of the Report

Chapter 2: Evolution of Organic Chemistry in the Pharmaceutical Industry

• Evolution of Organic and Medicinal Chemistry in Pharma
• Industrialization of Drug Discovery
• Advent of Combinatorial Chemistry
• Chemical Diversity
• Lead-Likeness and Drug-Likeness
• References

Chapter 3: Current Approaches to Organic and Medicinal Chemistry

• "Classical" Chemical Library Generation
  • Split-and-Mix Chemistry
  • Parallel Synthesis
• Newer Synthetic Approaches
  • tructure-Based and Fragment-Based Design
• Natural Products Renaissance
  • Diversity-Oriented Synthesis
  • Dynamic Chemical Libraries and Click Chemistry
    • Dynamic Chemical Libraries
    • Click Chemistry
• Chemogenomics
  • Role of the NIH
• Current Practices in Organic and Medicinal Chemistry in Pharma
• References

Chapter 4: Products and Services

• Technological Approaches of Vendors and Biopharmaceutical Companies
  • Structure-Based Design
  • Diversity-Oriented Synthesis
  • Chemogenomics
  • Multi-Component Reaction Chemistry
  • Other Approaches
• Product Offerings
• Service Offerings from Selected Vendors

Chapter 5: The Organic and Medicinal Chemistry Market

• The Competitive Environment
  • Business Models
  • Collaborations, Strategic Alliances, and Other Deals
• Market Analysis
• Market Survey Results
• General Observations
• References

Chapter 6: Company Profiles

• Accelrys, Inc.
• Albany Molecular Research, Inc.
• AnalytiCon Discovery GmbH
• ArQule, Inc.
• Asinex Ltd.
• Astex Therapeutics
• Biotage AB
• Cellular Genomics Inc.
• ChemBridge Corporation
• Chemical Diversity Labs, Inc.
• Daylight Chemical Information Systems, Inc.
• Discovery Partners International
• De Novo Pharmaceuticals Ltd.
• Eidogen-Sertanty, Inc.
• Enamine
• Evotec OAI
• Exelixis
• Graffinity Pharmaceuticals AG
• Infinity Pharmaceuticals
• Locus Pharmaceuticals
• Morphochem AG
• Nanosyn
• Nuevolution A/S
• Pharmacopeia Drug Discovery, Inc.
• Plexxikon Inc.
• Schrodinger, Inc.
• Structural GenomiX
• Surface Logix, Inc.
• Syrrx, Inc.
• Tripos, Inc.
• Vernalis plc

Chapter 7: Interviews With Industry Experts

• Michael Foley, Ph.D., Vice President, Chemistry, Infinity Pharmaceuticals
• Malcolm MacCoss, Ph.D., Vice President of Chemistry and Drug Discovery Sciences, Merck
• Horst Hemmerle, Ph.D., Head Lead Generation, Discovery Chemistry, Eli Lilly & Co.
• James Inglese, Ph.D., Director, Biomolecular Screening and Profiling Division, NIH Chemical Genomics Center
• Alexander S. Kiselyov, Ph.D., Vice President of Chemistry, Chemical Diversity Labs, Inc.
• Michael Morrissey, Ph.D., Senior VP of Discovery, Exelixis
• Steven Muskal, Ph.D., CEO, Eidogen-Sertanty, Inc.